Venus Aerospace successfully completed the flight test of its hypersonic engine, the first of an American-developed engine of its kind. Photo courtesy Venus Aerospace

Houston-based Venus Aerospace successfully completed the first U.S. flight test of its proprietary engine at a demonstration at Spaceport America in New Mexico.

Venus’ next-generation rotating detonation rocket engine (RDRE) is supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA and aims to enable vehicles to travel four to six times the speed of sound from a conventional runway. The recent flight test was the first of an American-developed engine of its kind.

"With this flight test, Venus Aerospace is transforming a decades-old engineering challenge into an operational reality,” Thomas d'Halluin, managing partner at Airbus Ventures, an investor in Venus, said in a news release. “Getting a rotating detonation engine integrated, launch-ready, and validated under real conditions is no small feat. Venus has shown an extraordinary ability to translate deep technical insight into hardware progress, and we're proud to support their bold approach in their attempt to unlock the hypersonic economy and forge the future of propulsion."

Venus’ RDRE operates through supersonic shockwaves, called detonations, that generate more power with less fuel. It is designed to be affordable and scalable for defense and commercial systems.

The RDRE is also engineered to work with the company's air-breathing detonation ramjet, the VDR2, which helps enable aircraft to take off from a runway and transition to speeds exceeding Mach 6. Venus plans for full-scale propulsion testing and vehicle integration of this system. Venus’ ultimate goal is to develop a Mach 4 reusable passenger aircraft, known as the Stargazer M4.

"This milestone proves our engine works outside the lab, under real flight conditions," Andrew Duggleby, Venus co-founder and chief technology officer, said in the release. "Rotating detonation has been a long-sought gain in performance. Venus' RDRE solved the last but critical steps to harness the theoretical benefits of pressure gain combustion. We've built an engine that not only runs, but runs reliably and efficiently—and that's what makes it scalable. This is the foundation we need that, combined with a ramjet, completes the system from take-off to sustained hypersonic flight."

The hypersonic market is projected to surpass $12 billion by 2030, according to Venus.

"This is the moment we've been working toward for five years," Sassie Duggleby, CEO and co-founder of Venus Aerospace, added in the release. "We've proven that this technology works—not just in simulations or the lab, but in the air. With this milestone, we're one step closer to making high-speed flight accessible, affordable, and sustainable."

Venus Aerospace has used a Small Business Innovation Research (SBIR) grant from NASA to develop new features of its compact rocket engine for hypersonic flights. Photo courtesy of Venus Aerospace.

Houston space tech company develops new hypersonic engine features with NASA funding

testing 1, 2, 3

Outfitted with a new type of aerospace technology, a rocket engine developed by Houston startup Venus Aerospace for hypersonic flights will undergo testing this summer.

Supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA, Venus Aerospace came up with a new design for nozzles — engine parts that help manage power — for its compact rocket engine. Venus Aerospace says the newly configured nozzles have “exceeded expectations” and will be incorporated into Venus’ upcoming ground-based engine testing.

“We’ve already proven our engine outperforms traditional systems on both efficiency and size,” Venus Aerospace CEO Sassie Duggleby says. “The technology we developed with NASA’s support will now be part of our integrated engine platform — bringing us one step closer to proving that efficient, compact, and affordable hypersonic flight can be scaled.”

The engine at the heart of Venus’ flight platform is called a rotating detonation rocket engine (RDRE). Venus says it’s the first U.S. company to make a scalable, affordable, flight-ready RDRE.

Unlike conventional rocket engines, Venus’ RDRE operates through supersonic shockwaves, called detonations, that generate more power with less fuel.

“This is just the beginning of what can be achieved with Venus propulsion technology,” says Andrew Duggleby, chief technology officer at Venus, founded in 2020. “We’ve built a compact high-performance system that unlocks speed, range, and agility across aerospace, defense, and many other applications. And we’re confident in its readiness for flight.”

Last fall, the company unveiled a high-speed engine system that enables takeoff, acceleration, and hypersonic cruising — all powered by a single engine. While most high-speed systems require multiple engines to operate at different speeds, Venus’ innovation does away with the cost, weight and complexity of traditional propulsion technology.

Among other applications, the Venus system supports:

  • Spacecraft landers
  • Low-earth-orbit satellites
  • Vehicles that haul space cargo
  • Hypersonic drones and missiles
Venus Aerospace announced that it's successfully ran the first long-duration engine test of their Rotating Detonation Rocket Engine in partnership with DARPA. Screenshot via Venus Aerospace

Houston space tech startup reports milestone achievement in partnership with federal agency

taking flight

A Houston tech company working on an engine to enable hypersonic flights has reported its latest milestone.

Venus Aerospace announced that it's successfully ran the first long-duration engine test of their Rotating Detonation Rocket Engine in partnership with Defense Advanced Research Projects Agency, or DARPA.

The RDRE engine Venus is working on is uniquely designed and a first in the field. It has an additional 15 percent efficiency over traditional rocket engines.

"As we continue to push towards our ultimate mission of high-speed global flight, this is an important technical milestone for having a flight-ready engine," Andrew Duggleby, CTO and co-founder of Venus Aerospace, says in the news release. "I'm incredibly proud of our team as they continue to push forward on this world-changing technology."

The test results are a big win, as the RDRE had previously only been tested in a short-duration capacity. DARPA is just one of several U.S. Government agencies that has contracts with Venus.

"The successful test is a testament to our team's dedication and expertise. We're building something special here at Venus, in large part because we have the right people and the right partners," Sassie Duggleby, CEO and co-founder of Venus Aerospace, adds. "I can't say enough about our collaboration with DARPA and the role they played in helping us make this leap forward."

Last summer, Venus added a new investor to its cap table. Andrew Duggleby founded Venus Aerospace with his wife and CEO Sassie in 2020, before relocating to the Houston Spaceport in 2021. Last year, Venus raised a $20 million series A round. Sassie joined the Houston Innovators Podcast a year ago to explain her company's mission of "home for dinner."

DARPA Partnership Long-Duration Testwww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”